1-(nitrosooxy)propan-2-ol
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 2, 2021 (NCT04891354)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05699486 | Phase 2 | Oct 23, 2022 | Attgeno AB, Aurevia |
| NCT04885491 | Phase 1/Phase 2 (Phase 2) | May 7, 2021 | Attgeno AB, Danderyds Hospital, Orebro University, Vinnova |
| NCT04891354 | Phase 1 | Feb 2, 2021 | Attgeno AB, Clinical Trial Consultants AB |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Attgeno AB | For profit | 3 | 3 | 2 | 2021 |
| Aurevia | For profit | 1 | 0 | 1 | 2022 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2021 |
| Danderyds Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Orebro University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Vinnova | Government | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1